Cargando…

The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells

AIMS/HYPOTHESIS: Classically, type 1 diabetes is thought to proceed to absolute insulin deficiency. Recently developed ultrasensitive assays capable of detecting C-peptide under 5 pmol/l now allow very low levels of C-peptide to be detected in patients with long-standing type 1 diabetes. It is not k...

Descripción completa

Detalles Bibliográficos
Autores principales: Oram, Richard A., Jones, Angus G., Besser, Rachel E. J., Knight, Bridget A., Shields, Beverley M., Brown, Richard J., Hattersley, Andrew T., McDonald, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855529/
https://www.ncbi.nlm.nih.gov/pubmed/24121625
http://dx.doi.org/10.1007/s00125-013-3067-x
_version_ 1782294933492727808
author Oram, Richard A.
Jones, Angus G.
Besser, Rachel E. J.
Knight, Bridget A.
Shields, Beverley M.
Brown, Richard J.
Hattersley, Andrew T.
McDonald, Timothy J.
author_facet Oram, Richard A.
Jones, Angus G.
Besser, Rachel E. J.
Knight, Bridget A.
Shields, Beverley M.
Brown, Richard J.
Hattersley, Andrew T.
McDonald, Timothy J.
author_sort Oram, Richard A.
collection PubMed
description AIMS/HYPOTHESIS: Classically, type 1 diabetes is thought to proceed to absolute insulin deficiency. Recently developed ultrasensitive assays capable of detecting C-peptide under 5 pmol/l now allow very low levels of C-peptide to be detected in patients with long-standing type 1 diabetes. It is not known whether this low-level endogenous insulin secretion responds to physiological stimuli. We aimed to assess how commonly low-level detectable C-peptide occurs in long-duration type 1 diabetes and whether it responds to a meal stimulus. METHODS: We performed a mixed-meal tolerance test in 74 volunteers with long-duration (>5 years) type 1 diabetes, i.e. with age at diagnosis 16 (9–23) years (median [interquartile range]) and diabetes duration of 30 (19–41) years. We assessed fasting and stimulated serum C-peptide levels using an electrochemiluminescence assay (detection limit 3.3 pmol/l), and also the urinary C-peptide:creatinine ratio (UCPCR). RESULTS: Post-stimulation serum C-peptide was detectable at very low levels (>3.3 pmol/l) in 54 of 74 (73%) patients. In all patients with detectable serum C-peptide, C-peptide either increased (n = 43, 80%) or stayed the same (n = 11) in response to a meal, with no indication of levels falling (p < 0.0001). With increasing disease duration, absolute C-peptide levels fell although the numbers with detectable C-peptide remained high (68%, i.e. 25 of 37 patients with >30 years duration). Similar results were obtained for UCPCR. CONCLUSIONS/INTERPRETATION: Most patients with long-duration type 1 diabetes continue to secrete very low levels of endogenous insulin, which increase after meals. This is consistent with the presence of a small number of still functional beta cells and implies that beta cells are either escaping immune attack or undergoing regeneration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-013-3067-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-3855529
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-38555292013-12-11 The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells Oram, Richard A. Jones, Angus G. Besser, Rachel E. J. Knight, Bridget A. Shields, Beverley M. Brown, Richard J. Hattersley, Andrew T. McDonald, Timothy J. Diabetologia Article AIMS/HYPOTHESIS: Classically, type 1 diabetes is thought to proceed to absolute insulin deficiency. Recently developed ultrasensitive assays capable of detecting C-peptide under 5 pmol/l now allow very low levels of C-peptide to be detected in patients with long-standing type 1 diabetes. It is not known whether this low-level endogenous insulin secretion responds to physiological stimuli. We aimed to assess how commonly low-level detectable C-peptide occurs in long-duration type 1 diabetes and whether it responds to a meal stimulus. METHODS: We performed a mixed-meal tolerance test in 74 volunteers with long-duration (>5 years) type 1 diabetes, i.e. with age at diagnosis 16 (9–23) years (median [interquartile range]) and diabetes duration of 30 (19–41) years. We assessed fasting and stimulated serum C-peptide levels using an electrochemiluminescence assay (detection limit 3.3 pmol/l), and also the urinary C-peptide:creatinine ratio (UCPCR). RESULTS: Post-stimulation serum C-peptide was detectable at very low levels (>3.3 pmol/l) in 54 of 74 (73%) patients. In all patients with detectable serum C-peptide, C-peptide either increased (n = 43, 80%) or stayed the same (n = 11) in response to a meal, with no indication of levels falling (p < 0.0001). With increasing disease duration, absolute C-peptide levels fell although the numbers with detectable C-peptide remained high (68%, i.e. 25 of 37 patients with >30 years duration). Similar results were obtained for UCPCR. CONCLUSIONS/INTERPRETATION: Most patients with long-duration type 1 diabetes continue to secrete very low levels of endogenous insulin, which increase after meals. This is consistent with the presence of a small number of still functional beta cells and implies that beta cells are either escaping immune attack or undergoing regeneration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-013-3067-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2013-10-12 2014 /pmc/articles/PMC3855529/ /pubmed/24121625 http://dx.doi.org/10.1007/s00125-013-3067-x Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Article
Oram, Richard A.
Jones, Angus G.
Besser, Rachel E. J.
Knight, Bridget A.
Shields, Beverley M.
Brown, Richard J.
Hattersley, Andrew T.
McDonald, Timothy J.
The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
title The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
title_full The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
title_fullStr The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
title_full_unstemmed The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
title_short The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
title_sort majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855529/
https://www.ncbi.nlm.nih.gov/pubmed/24121625
http://dx.doi.org/10.1007/s00125-013-3067-x
work_keys_str_mv AT oramricharda themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT jonesangusg themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT besserrachelej themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT knightbridgeta themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT shieldsbeverleym themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT brownrichardj themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT hattersleyandrewt themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT mcdonaldtimothyj themajorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT oramricharda majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT jonesangusg majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT besserrachelej majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT knightbridgeta majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT shieldsbeverleym majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT brownrichardj majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT hattersleyandrewt majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells
AT mcdonaldtimothyj majorityofpatientswithlongdurationtype1diabetesareinsulinmicrosecretorsandhavefunctioningbetacells